Centiva Capital’s Immunovant IMVT Stock Holding History

Centiva Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,700	Closed	-$422K	–	1802
2025 Q1	$422K	Buy	+24,700	New	+$517K	0.01%	899

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Centiva Capital's IMVT Position: Q1 2021 in Review

Centiva Capital sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 9,560 shares — an estimated $442K sold.

Centiva Capital first reported a position in IMVT in Q4 2020 and held it in 1 quarter. The position peaked at $442K in Q4 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

Centiva Capital reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
Centiva Capital sold 9,560 Immunovant shares in Q1 2021, an estimated $442K.
Centiva Capital first reported a position in Immunovant in Q4 2020 and held it in 1 quarter.
Centiva Capital's Immunovant position peaked at $442K in Q4 2020.
120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Centiva Capital's 13F filing for Q1 2021, filed 17 May 2021.